Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type
Part of paid clinical trials in Stanford, California.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT03728972
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)
- NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pembrolizumab — DRUG200mg IVPB every 3 weeks
Study Details
The purpose of this study is to test how well pembrolizumab shrinks Early-Stage NK/T-cell Lymphoma (ENKTL) in participants who have not yet received chemotherapy.
Key Dates
- Start date
- Nov 9, 2018
- Status verified
- Aug 2025
- Primary completion
- Jun 15, 2025
- Completion
- Nov 30, 2026
Study Design
- Enrollment
- 19 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Early-Stage NK/T-cell Lymphoma/ENKTL (Stage I/II)
- Experimental: Early-Stage NK/T-cell Lymphoma/ENKTL (Stage III/IV)
Primary Outcome Measure
Complete Response Rate of Pembrolizumab in Untreated Early-Stage NK/T-cell Lymphoma, Nasal Type (ENKTL) [ Time Frame: Up to 2 years ]
Locations (10)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | - |
| Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge | New Jersey | 07920 | - |
| Hackensack Meridian Health | Hackensack | New Jersey | 07601 | - |
| Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown | New Jersey | 07748 | - |
| Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale | New Jersey | 07645 | - |
| Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) | Commack | New York | 11725 | - |
| Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison | New York | 10604 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale | New York | 11553 | - |
| Md Anderson Cancer Center | Houston | Texas | 77030 | - |
Related coverage on Hipa.ai
- Pembrolizumab Shows 47% Complete Response in Early-Stage NK/T-cell LymphomaPembrolizumab · Oct 23, 2025 · ClinicalTrials.gov
Find similar trials in Stanford, CA
By research site
Stanford University· Stanford, CAMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJHackensack Meridian Health· Hackensack, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)· Commack, NY